ABSTRACT Although genome-wide association studies (GWAS) have successfully identified many risk loci associated with Alzheimer's disease (AD), the dispute about missing heritability and weak interpretability must be resolved to reveal the causal genes in the risk loci and explain the mechanism of AD. The aim of this study was to overcome the problems that involve moving from the risk loci to causal genes and to understand the genotype-to-phenotype relationship of AD. We integrated the prediction results from different methods (e.g., DAPPLE, DEPICT, Prix Fixe, etc.) based on GWAS data combining protein-protein interaction networks, gene functions, co-function networks or expression quantitative trait loci data. A total of 43 plausible causal genes of AD were identified, including eight high-confidence AD causal genes (BIN1, CR1, CLU, HMHA1, MS4A4A, MS4A6A, PICALM and PVR). Then the landscape of these 43 causal genes was generated. Gene Ontology analysis showed that these identified causal genes were enriched in lipid/lipoprotein-related complexes and processes, supporting that lipid/lipoprotein homeostasis has a critical role in AD. The distinct spatial-temporal expression patterns of these causal genes illustrated that they played diverse roles in different cell types and developmental stages. The top eight causal genes were dysregulated in AD cases compared with their expression in normal controls, indicating that these genes are important in the pathophysiology of AD. Results from our study could provide meaningful clues for understanding AD pathogenesis. Together, further functional validation of the causal genes of AD will help identify potential targets for AD therapy.
I. INTRODUCTION
Alzheimer's disease (AD) is an age-related progressive neurodegenerative disorder and characterized by accelerated neuronal loss leading to dementia [1] . Its pathological hallmarks are extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangle composed of microtubule-associated protein tau (Tau) in disease brain tissues [2] . Genetic regulation during ageing has been reported to play a pivotal role in the occurrence and development of AD [3] . The genetic epidemiology of AD has advanced
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over the last decade, and numerous independent loci in APP, PSEN1, PSEN2 and APOE have been found to be associated with AD [4] , [5] . As an experimental design based on disease and non-disease groups, genome-wide association studies (GWAS) have been performed to identify genetic risk factors by uncovering the associations between single nucleotide polymorphisms (SNPs) and complex diseases.
In the past few years, GWAS have achieved great success in identifying numerous risk loci for AD [6] , [7] . Despite the remarkable advances in research that have been made on the genetic basis of AD, the pathophysiology of AD is not well elucidated. Translating genetic findings into molecular risk mechanisms remains a challenge.
The investigation of causal genes plays an important role in understanding the mechanisms of AD pathogenesis and the development of new therapeutic targets. Although a number of risk loci have been found, few causal genes have been identified from these loci [6] , [8] , [9] . Intuitively, the genes in closest physical proximity to the top associated variants are the most likely causal genes. However, some examples in recent studies suggest that the causal genes are distinct from the nearest genes [10] . Moreover, because of the complicated linkage disequilibrium (LD) between SNPs and causative variants and sampling errors in test statistics, the exerted effects of variants on AD are unknown. Moving from the risk loci to causal genes remains challenging, and a precise understanding of the genotype-to-phenotype relationship of AD remains elusive.
To overcome these problems, several GWAS-based prioritization methods combining different networks and gene function or gene expression data have been proposed. For example, Disease Association Protein-Protein Link Evaluator (DAPPLE) [11] integrates with GWAS data and protein-protein interaction (PPI) networks to prioritize the diseases associated with causal genes; Data-driven Expression Prioritized Integration for Complex Traits (DEPICT) [12] integrates GWAS data and predicted gene functions to identify causal genes; Prix Fixe (PF) [13] identifies potential causal genes using shared-function or co-function networks; Simultaneously Inference of GeNEs and Tissues (SIGNET) [14] , based on the Bayesian approach, prioritizes potential causal genes through integrating GWAS and multiple tissue-specific gene networks; and Sherlock [15] and summary data-based Mendelian randomization (SMR) [16] predict causal genes by combining GWAS and expression quantitative trait loci (eQTL) data. SMR is similar to Sherlock, however, the statistical inference of SMR is different from that of Sherlock.
In this study, we integrated the prediction results from different methods, including DAPPLE, DEPICT, Prix Fixe, Sherlock, SIGNET and SMR, to generate plausible causal genes for AD. The largest GWAS for late-onset AD provided by the International Genomics of Alzheimer's Project (IGAP) was used as the input file for the different approaches [6] . Then, we conducted Gene Ontology (GO) analyses, distinct spatial-temporal expression and dysregulated expression between AD and normal controls to explore the roles of these causal genes in AD. The investigation of causal genes could provide information and evidence to explore the genetic and pathophysiological mechanisms for AD.
II. METHODS

A. GWAS DATA OF AD
IGAP reported the largest GWAS data of AD to date [6] . In stage 1, the meta-analysis results included genotyped and inputted data (7,055,881 SNPs, 1000G phase 1 alpha imputation, Build 37, Assembly Hg19) of 17,008 AD cases and 37,154 normal controls with meta-analysis P-values using regression coefficients. In stage 2, the meta-analysis results of the 11,632 SNPs were genotyped and tested in an independent set of 8,572 AD cases and 11,312 normal controls [6] . The genome-wide SNP associations from stage 1 of IGAP were used in this study. More detailed information on IGAP can be found in the original paper [6] , and the GWAS data can be downloaded from http://web.pasteurlille.fr/en/recherche/u744/igap/igap_download.php.
B. PRIORITIZATION OF AD CANDIDATE CAUSAL GENES
We scored each gene by adopting the following seven selection criteria and calculating the number of satisfied criteria: (1) genes prioritized by DAPPLE with a gene-based P-value < 0.05 [11] ; (2) genes prioritized by DEPICT with a gene-based false discovery rate (FDR) < 0.05 [12] ; (3) genes identified by the GWAS data from IGAP provided by Lambert et al. [6] ; (4) genes prioritized by PF with a gene-based PF score ≥ 0.1 [13] ; (5) genes prioritized by Sherlock with a logarithm of Bayes Factor (LBF) ≥ 5.00 [15] ; (6) genes prioritized by SIGNET with an FDR < 0.05 [14] ; and (7) genes prioritized by SMR with P-value SMR < 8.4E-06 and P-value HEIDI > 0.05 [16] . More detailed information about these approaches shown in the Supplementary Methods.
The methods mentioned above are combining data from different biological aspects, including eQLT data, PPI network, and co-function network or gene functions. And they are complementary with each other. Therefore, we scored genes by these methods with equal weights. If one of the above satisfied criteria identified it as a prioritized gene, the candidate causal gene was assigned with a score of 1 point; if a gene was identified by two satisfied criteria, the total score of the gene is 2 points. Then, the prioritized genes were ranked by the cumulative scoring strategy. The higher the total score of the candidate causal gene is the higher probability that the prioritized gene is an AD causal gene.
C. GO ANALYSIS OF AD CANDIDATE CAUSAL GENES
GO analysis of the AD prioritized causal genes was performed using the online biological tool, Database for Annotation, Visualization and Integrated Discovery (DAVID 6.7, https://david-d.ncifcrf.gov/) [17] . In DAVID, the significance of a term is defined by the threshold with Benjamini-Hochberg adjusted P-value < 0.05.
D. GENE EXPRESSION ANALYSIS IN DIFFERENT BRAIN CELL TYPES
The expression of AD prioritized causal genes was investigated in six specific brain cell types, including endothelial cells, fetal astrocytes, mature astrocytes, microglia/ macrophage, neurons and oligodendrocytes. The RNA sequencing (RNA-seq) data were obtained from the database of Brain RNA-Seq (http://www.brainrnaseq.org/) [18] . In addition, log 2 (FPKM + 1) (where FPKM is the fragments per kilobase of transcript sequence per million mapped reads) VOLUME 7, 2019 was used to represent the gene expression level. A paired Wilcoxon test was used to compare the statistical significances of expression differences among the different brain cell types.
E. GENE EXPRESSION ANALYSIS IN FOUR AGE CATEGORIES
The RNA-seq data of the AD plausible causal genes from the blood of Homo sapiens straitified by different age groups were downloaded from SOFT-formatted family files of the GSE75337 and GSE103232 [19] datasets from the Gene Expression Omnibus database (GEO, https://www.ncbi.nlm.nih.gov/geo/). The two datasets were obtained using the Illumina HiSeq 2500 platform. There were four age groups including 24-29, 45-50, 60-65 and 75-80 years of age, corresponding to 15, 17, 15 and 15 samples, respectively. The gene expression level is represented by the mean value of log 2 (RPKM + 1), where RPKM is the reads per kilobase per million mapped reads.
F. GENE EXPRESSION ANALYSIS IN AD CASES AND NORMAL CONTROLS
The expression data of the causal genes in AD cases and normal controls were downloaded from SOFT-formatted family files of the GSE5281 and GSE48350 datasets from the GEO database. The two datasets were obtained using Affymetrix Human Genome U133 Plus 2.0 Array. GSE5281 contains 10 AD cases and 13 normal controls, and GSE48350 contains 28 AD cases and 57 normal controls. We investigated the gene expression data from the entorhinal cortex (EC) and hippocampus (HIP). A log 2 transformation of the expression data was applied. For the expression data, the probe IDs were mapped to the Entrez IDs; furthermore, for a gene with more than one probe ID, the median value of these probes was selected for further analysis. The Wilcoxon test was used to determine the statistical significance of the expression difference.
III. RESULTS
A. AD CAUSAL GENES IDENTIFIED BY DIFFERENT METHODS
The AD plausible causal genes prioritized by different criteria are as follows: (1) Table S7 ). More details of these methods were shown in the Supplementary Methods.
Based on the cumulative scoring strategy, we ranked the potential causal genes on account of the total scores. The higher the total score of the gene is the higher probability that the prioritized gene is an AD causal gene. Eventually, 43 plausible causal genes with total score ≥ 2 were identified through systematically integrating the prediction results from the different methods (FIGURE 1). There were eight genes (BIN1, CR1, CLU, HMHA1, MS4A4A, MS4A6A, PICALM and PVR) with scores ≥ 4, indicating that these eight genes were the most promising causal genes for AD. The other 35 genes with 2 or 3 points were supported as plausible causal genes by three or two different predictors.
B. GO ANALYSIS OF THE PLAUSIBLE CAUSAL GENES
GO analysis revealed a more detailed biological function spectrum of these AD causal genes, and the top enriched GO terms with corrected P-values < 0.05 are listed in FIGURE 2. Among the cellular component terms overrepresented in the causal gene set, various lipoprotein particles (e.g., high-density lipoprotein, low-density lipoprotein and triglyceride-rich lipoprotein) and protein-lipid complexes were included (FIGURE 2A). According to previous findings, these components correlated with brain Aβ levels are involved in the development of AD [20] - [22] . Additionally, when biological processes were used as keywords, some lipid/lipoprotein-related processes (e.g., phospholipid efflux/transport, lipid localization/transport) were included (FIGURE 2B). Moreover, there were no significantly enriched GO terms for molecular function. Overall, these GO enrichment terms were primarily associated with lipid/lipoprotein-related particles and the enriched processes demonstrated the importance of lipid/lipoprotein in the AD development.
C. EXPRESSION ANALYSIS OF CAUSAL GENES IN DIFFERENT CELL TYPES
Profiling the spatial-temporal expression pattern and characterizing the variation tendency of causal genes are vital for understanding the role of these genes in the pathophysiology of AD. To investigate the diverse spatial expression patterns, we explored the expression of the 43 plausible causal genes in six different cell types (endothelial cells, fetal astrocytes, mature astrocytes, microglia/macrophage, neurons and oligodendrocytes) in the central nervous system (CNS) (FIGURE 3A) and found that the expression levels of the top-ranked causal genes (with scores ≥ 3, such as CLU, PICALM, APOC1, APOC2, APOE and SORL1) were higher in these CNS cell types than in the low-scored genes (with scores = 2). In addition, the average expression level of the top-ranked 22 causal genes (with scores ≥ 3) in microglia/macrophage was higher than that in other CNS cell types (FIGURE 3B). Microglia/macrophage is the principal immune cells in the CNS and plays a significant role in the host defence against invading microorganisms [23] . These genes may have important roles in immunity associated with the pathology of AD.
D. EXPRESSION ANALYSIS OF CAUSAL GENES STRATIFIED BY AGE GROUPS
Prevalence studies on AD have reported a positive association with age, therefore, we performed an expression analysis of these plausible causal genes in different age categories: 24-29, 45-50, 60-65 and 75-80 years of age. These causal genes showed distinct temporal expression patterns in blood samples (FIGURE 4). According to expression patterns, the causal genes were classified into four categories: the genes (e.g., BIN1, CLU, and PVR, etc.) in the first category (gene symbols are marked by green in FIGURE 4) are highly expressed in the middle age (45-50 years) stage, then decline with age; the genes (e.g., MS4A6A and PICALM, etc.) in the second category (marked by red in FIGURE 4) are highly expressed with age, and achieved the highest expression level in the oldest old (75-80 years) stage; the genes (e.g., CR1 and HMHA1, etc.) in the third category (marked by blue in FIGURE 4) are highly expressed in the middle age stage, decline at the age stage of 60-65 years, and then According to different expression patterns, the causal genes were classified into four categories: 1) genes marked by green are lowly expressed in the old; 2) genes marked by red are highly expressed in the old; 3) genes marked by blue are lowly expressed in older old, then highly expressed in oldest old; 4) genes marked by orange are highly expressed in older old, the lowly expressed in oldest old.
increase in the oldest old stage; the genes of DSG2, NDUFS3 and TRAPPC6A in the last category (marked by orange in FIGURE 4) have high expression levels at age stage of 60-65 years and are lowly expressed in the middle age and oldest old stages. We also explored the expression of the high-confidence plausible causal genes (the top 22 genes with Figure S1 ). According to the expression patterns, the top 22 genes are also classified into five categories: 1) increased at the fetal and infancy stages, equilibrium at the adulthood stage; 2) increased with age from the fetal to adulthood stage; 3) maintained a relatively stable level from the fetal to adulthood stage; 4) declined with age from the fetal to adulthood stage; and 5) increased at the fetal and infancy stages, declined at the adulthood stage. The genes in the different expression pattern categories are marked by different colors in Supplementary Figure S1 . These expression patterns in the blood and different brain regions illustrate that these causal genes play diverse roles at different human developmental stages.
E. EXPRESSION ANALYSIS OF AD CAUSAL GENES IN AD AND NORMAL BRAIN REGIONS
To further investigate the effects of the causal genes in AD, we compared the gene expression levels between AD cases and normal controls in different brain regions (HIP and EC) (FIGURE 5 and Supplementary Table S8 ). The top eight genes (BIN1, CR1, CLU, HMHA1, MS4A4A, MS4A6A, PICALM and PVR) with scores ≥ 4 had significantly different expression levels between AD cases and normal controls in the HIP or EC. Furthermore, the top two genes (BIN1 and CR1) had different regulated patterns in the HIP and EC: BIN1 is downregulated and CR1 is upregulated in AD cases (FIGURE 5A). There were two genes, CEACAM19 and MARK4 (with scores = 2) that showed an inverse regulation of gene expression in the HIP and EC (FIGURE 5B). In the HIP, CEACAM19 and MARK4 were significantly upregulated, but in the EC, they were significantly downregulated, showing brain region-specific expression. The dysregulation expression analysis of the 43 AD candidate causal genes in the HIP and EC from the GSE5281 and GSE48350 datasets is shown in Supplementary Table S8. These results suggested that the top AD causal genes are dysregulated in cases, supporting that these genes may represent authentic causal genes for AD.
IV. DISCUSSION
In recent years, great progress has been made to explore the molecular mechanisms of AD. Investigating the causal genes of AD is very important for understanding AD pathogenesis and developing new therapeutic targets. With the development of high-throughput genotyping, researchers are able to uncover genetic risk variants for AD by performing multiple GWASs in different populations, and numerous risk loci have been identified [6] , [8] , [24] . However, moving from risk loci to causal genes remains challenging. To overcome this problem, in this study, we systematically integrated the prediction results from several GWAS-based prioritization methods combining different gene annotation data (such as network, gene function or eQTL data) and identified 43 AD high-confidence plausible causal genes. Of note, 14 of these 43 causal genes were also identified as risk genes in AlzGene (the top ten AD genes) [24] and in the study by Karch et al. 2015 [25] (Supplementary Figure S2 and Table S9 ). Moreover, by comparing with document numbers (searching Pubmed database using gene symbol and Alzheimer keywords in the [Tittle/Abstract]) of non-causal genes in 507 non-causal gene datasets, these of causal genes were all significantly higher with P-value < 0.05 (Supplementary Methods and Figure S3 ), further supporting that these genes might play important roles in AD.
Among the 43 prioritized causal genes, BIN1, CR1, CLU, HMHA1, MS4A4A, MS4A6A, PICALM and PVR represent VOLUME 7, 2019 the AD causal genes with the highest confidence. As a member of the Bin1/amphiphysin/RVS167 family, bridging integrator 1 is encoded by BIN1, which is located on chromosome 2q14.3, and involved in regulating endocytosis and trafficking, the immune response, calcium homeostasis and apoptosis [25] . Previous studies have revealed that BIN1 is associated with AD, and SNPs rs7561528 and rs744373 in BIN1 could increase the risk for AD [8] , [26] . Additionally, recent studies showed that the downregulation of BIN1, increases the generation of polarized endogenous Aβ and promotes the progression of Tau pathology, induces Aβ and Tau accumulation in neurons, and increases AD risk [27] , [28] . CR1, located on chromosome 1q32, encodes the main receptor of the complement C3b protein. Pathways involving C3b and CR1 proteins are involved in the complement activation and could mediate complement-driven phagocytosis that fosters Aβ clearance [24] . As a complement factor, CR1 expression is upregulated in the affected regions of AD brains [29] , and the SNPs rs6656401 and rs3818361 in CR1 are associated with AD risk [24] . CLU is located on chromosome 8p21.1 and encodes the apolipoprotein clusterin, which is found to co-localize with Aβ in the amyloid deposits of AD brains. Multiple studies have shown evidence of a protective role of clusterin in AD pathogenesis, such as in the prevention of Aβ-induced neurotoxicity, clearance of Aβ, inhibition of the complement system and neuronal apoptosis, and promotion of neurite outgrowth [30] , [31] . The AD risk SNPs rs11136000 and rs9331888 in CLU are associated with a decrease in clusterin plasma levels [31] . HMHA1 (also known as ARHGAP45) is located on chromosome 19p13.3 and encodes the minor histocompatibility antigen HA-1. The function of HMHA1 in AD remains largely unknown. Previous evidence has suggested that HMHA1 is a major target of immune responses after allogeneic stem cell transplantation applied for the treatment of leukemia and solid tumors [32] . However, recent studies showed that HMHA1 is associated with melanoma, significantly promoting melanoma cell proliferation, invasion and migration, and preventing cell apoptosis [33] . These results suggest that HMHA1 may play an important role in AD development. Both located on chromosome 11q12.2, MS4A4A and MS4A6A are members of the membrane-spanning 4-domains subfamily A, which participate in the regulation of Ca 2+ signaling and play pivotal roles in immunity [34] . Previous studies have shown that the expression levels of MS4A4A and MS4A6A were increased in the brain tissue of autopsied AD patients, confirming that the elevated expression levels of these genes in the cerebellum and frontal cortex may well be related to disease status, whether through genetic influence or other factors [35] . PICALM is located on chromosome 11q14 and encodes the phosphatidylinositol binding clathrin assembly protein. It is involved in reversing the recruitment of clathrin and mediating endocytosis, and protects neurons against Aβ toxicity. Several studies have suggested that endothelial PICALM plays an important role in Aβ clearance and transcytosis across the blood-brain barrier, which is critical for the regulation of Aβ levels and homeostasis in the brain [36] . Located on chromosome 19q13.31, PVR encodes the poliovirus receptor. Poliovirus is the causative agent of an acute disease in the CNS, poliomyelitis. The function of PVR on AD remains largely unknown. Previous studies have revealed that PVR overexpression correlates with the malignant phenotype in cutaneous melanoma and is crucial for invasiveness of lung cancer cells, and have identified that the overexpression of PVR is responsible at least partly for the enhanced motility and proliferation of cancer cells [37] . These results suggest that PVR may play a critical role in the motility and proliferation of neurons. Overall, these results strongly suggest that the top eight high-confidence AD causal genes are important for AD pathology.
To better understand the AD mechanism, we also explored the context of cellular components and biological processes and found that the 43 AD causal genes were enriched in lipid/lipoprotein-related complexes and processes (FIGURE 2). Brain lipid/lipoprotein homeostasis plays a critical role in AD, particularly affecting Aβ processing, clearance and aggregation, as well as neuro-toxicities for AD pathogenesis [38] . Moreover, the analysis of lipid/lipoprotein composition in plasma and cerebrospinal fluid could improve our understanding of AD development and progression, which could potentially serve as disease biomarkers and prognostic indicators for AD therapies [38] , [39] . In addition, based on numerous studies, physically interacting genes are more likely to share common functions. Therefore, to further investigate the pathological interaction network of AD causal genes, we also constructed an AD-specific gene-gene interaction network from the GeneMANIA Human Database [40] . As shown in Supplementary Figure S4 Figure S4 ) and may be involved in the pathological process of the AD phenotype. For example, APP encodes amyloid β precursor protein and is a key gene in AD progression, and the overexpression of APP is related to AD pathology [41] . Additionally, some genes (e.g., APOA2, CLUAP1, CNTF, DSC1, NFKB1, PLA2G3 and RB1CC1) have been shown to be related to AD in several studies [42] - [48] .
Furthermore, the top 22 causal genes are highly expressed in microglia/macrophage cells, especially APOC2, APOC1, PICALM and MS4A4A (FIGURE 4A). Microglia/macrophage cells are well-known to act as the main form of active immune defense in the CNS. The high expression level of these genes in the cells suggests that these genes may be associated with neuro-immunity by regulating the function of microglia/macrophage cells [49] . In addition, between AD cases and normal controls, the top eight genes had different regulated patterns in the HIP or EC: three genes (BIN1, CLU and PVR) were significantly downregulated and five genes (CR1, HMHA1, MS4A4A, MS4A6A and PICALM) were significantly upregulated in the AD cases (Supplementary  Table S8 ). These results suggest that these genes play central regulatory roles in AD progression, and are vital for both understanding the pathophysiology of AD and discovering potential targets for drug treatment. As suggested above, more experimental work is needed to elucidate the role of these genes.
Additionally, the significant SNPs under the causal genes identified by Sherlock and SMR integrating GWAS data and brain eQTL data may be the causative SNPs for AD. To investigate the regulatory effect of the significant SNPs on gene expression, we genotyped these SNPs in the HIP with Braineac data [50] (Supplementary Table S10 and Figure S5 ). SNP rs4844610, located in CR1, is associated with a faster rate of cognitive decline in AD and an enhanced burden of amyloid plaques [51] . In Supplementary Figure S5A , rs4844610 with the A allele upregulates the expression level of CR1 in the HIP, which is consistent with the result of CR1 dysregulation between AD cases and normal controls in different brain regions (shown in FIGURE 5A ). SNP 4663100, located between BIN1 and CYP27C1, may be associated with AD and Tau modulation [52] . With the C allele, rs4663100 downregulates the expression level of BIN1 in the HIP (Supplementary Figure S5B) , which is consistent with the result of BIN1 dysregulation in AD in HIP (FIGURE 5A). Taken together, rs4844610 with the A allele and rs4663100 with the C allele may be risk factors for AD and promote AD progression. Furthermore, the detail information of these significant SNPs under AD causal genes was shown in Table S10 (Supplementary Tables). It was found that most of these SNPs located in non-coding regions, and upregulated or downregulated the expression levels of causal genes in the HIP significantly. Maybe investigation of these SNPs will advance the understanding of the mechanism of AD.
To overcome the problem of moving from the risk loci to causal genes and to better understand the mechanism of AD, we systematically integrated the prediction results of several GWAS-based approaches combining eQTL data, PPI network, and co-function networks or gene functions. Additionally, we generated the landscape of these causal genes. However, there are some limitations in this study. Firstly, these bioinformatics methods are all based on GWAS data from IGAP, which provided the largest AD GWAS data. Nevertheless, it is well known that the number of risk loci increases with increasing sample sizes of traits, and there has been no trait with evidence of a plateau [53] . Therefore, the sample size of IGAP may limit the number of AD risk loci and causal genes. Second, the genes supported by more than one method (score ≥ 2) were identified as candidate causal genes, but some genes supported by a single prediction approach might also have important roles in AD. Thus, some important AD causal genes may be missed in our analysis. Thirdly, because of the lack of gold-standard test dataset for AD causal genes, we can't evaluate the accuracy of the six methods applied to predict AD causal genes. Moreover, the six methods are combining data from different biological aspects, including eQLT data, PPI network, and co-function network or gene functions. And these methods are complementary with each other. Therefore, we scored genes by the six methods with equal weights. We will consider an integrated method combining GWAS and multi-omics data with different weights in the further study. Furthermore, though a number of promising causal genes were identified in this study, further genetic and functional experiments in AD models are needed to validate the role of these genes in AD. Meanwhile, further genetic and functional validation of these genes will progress mechanistic insights into AD pathogenesis and may facilitate to identify targets for AD therapeutics and diagnostics.
V. CONCLUSION
We systematically integrated the prediction results from different approaches based on GWAS data combining eQTL data, PPI network, and co-function network or gene functions and identified 43 AD candidate causal genes including the causal genes determined in previous studies and some novel causal genes. Then, we generated the landscape of these AD causal genes. GO analysis further showed that the identified causal genes were enriched in lipid/lipoprotein-related complexes and processes, supporting the notion that brain lipid/lipoprotein homeostasis may have a critical role in AD. The distinct spatial-temporal expression of these causal genes illustrated that they played diverse roles in different human CNS cell types and during different developmental stages. Of note, the top eight causal genes were dysregulated in the AD cases compared with the normal controls, indicating that these genes are important in the pathophysiology of AD. All of the top eight causal genes showed a significant association with AD regarding different biological processes. The systematic and comprehensive analysis in this study is expected to aid in the exploration of the molecular mechanisms underlying AD. Further genetic and functional validation of AD causal genes will not only improve the understanding of the effect of genetic factors on AD pathogenesis, but will also aid in the identification of potential targets for AD treatment.
